Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Robert W. Baird

Robert W. Baird upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from an underperform rating to a neutral rating in a research note published on Wednesday morning, Briefing.com Automated Import reports. Robert W. Baird currently has $18.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $22.00.

Other equities analysts have also issued research reports about the company. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the stock a buy rating in a research report on Friday, August 16th. BidaskClub lowered Theravance Biopharma from a sell rating to a strong sell rating in a research report on Friday, October 25th. Piper Jaffray Companies reaffirmed a buy rating on shares of Theravance Biopharma in a research report on Monday, September 9th. Finally, HC Wainwright began coverage on Theravance Biopharma in a report on Tuesday, October 29th. They issued a buy rating and a $25.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $33.40.

Shares of Theravance Biopharma stock opened at $17.60 on Wednesday. The firm has a market capitalization of $969.63 million, a P/E ratio of -4.41 and a beta of 1.66. The business has a fifty day simple moving average of $18.19 and a two-hundred day simple moving average of $19.29. Theravance Biopharma has a 12 month low of $15.18 and a 12 month high of $29.45.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.05) EPS for the quarter, meeting the consensus estimate of ($1.05). The firm had revenue of $12.43 million for the quarter, compared to analysts’ expectations of $13.33 million. As a group, equities analysts expect that Theravance Biopharma will post -4.29 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its stake in shares of Theravance Biopharma by 68.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,798 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 732 shares during the period. Simplex Trading LLC grew its stake in shares of Theravance Biopharma by 30.1% during the 3rd quarter. Simplex Trading LLC now owns 5,043 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,167 shares during the period. Opti Capital Management LP bought a new stake in shares of Theravance Biopharma during the 2nd quarter valued at about $1,303,000. Quadrant Capital Group LLC bought a new stake in shares of Theravance Biopharma during the 3rd quarter valued at about $32,000. Finally, Northern Trust Corp grew its stake in shares of Theravance Biopharma by 0.6% during the 2nd quarter. Northern Trust Corp now owns 553,629 shares of the biopharmaceutical company’s stock valued at $9,041,000 after purchasing an additional 3,547 shares during the period. Institutional investors own 83.68% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Further Reading: How interest rates affect municipal bond prices

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.